XML 51 R44.htm IDEA: XBRL DOCUMENT
v3.25.3

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Nov. 30, 2024 | Jul. 31, 2023 | Jan. 31, 2022 | Aug. 31, 2018 | Mar. 31, 2025 | Sep. 30, 2018 | Sep. 30, 2025 | Sep. 30, 2023 | Dec. 31, 2024 | Sep. 30, 2024 | Dec. 31, 2023
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Restricted cash |  |  |  |  |  |  | $ 9,471 |  | $ 8,770 | $ 8,770 | $ 5,770
Letter of Credit | Corporate Credit Card Program |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Restricted cash |  |  |  |  |  |  | 5,000 |  |  |  |
Letter of Credit | Fleet Program |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Restricted cash |  |  |  |  |  |  | 400 |  |  |  |
Stoke Therapeutics, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments payable |  |  | $ 245,000 |  |  |  |  |  |  |  |
Stoke Therapeutics, Inc. [Member] | Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront consideration and transaction costs |  |  | $ 60,000 |  |  |  |  |  |  |  |
Collaboration agreement description |  |  | Under the collaboration, the two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits with respect to a SYNGAP1 program |  |  |  |  |  |  |  |
License Agreements [Member] | North America |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments payable |  |  |  |  |  |  | 40,000 |  |  |  |
License Agreements [Member] | Neuren Pharmaceuticals Limited [Member] | North America |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Proceeds from Sale of Intangible Assets |  |  |  |  |  |  |  |  | 146,500 |  |
Upfront payment |  | $ 100,000 |  |  |  |  |  |  |  |  |
Upfront license fee |  |  |  | $ 10,000 |  |  |  |  |  |  |
Milestone payment as intangible asset |  |  |  |  |  |  | 40,000 |  |  |  |
PRV liability |  |  |  |  |  |  | 29,600 |  | $ 19,200 |  |
License Agreements [Member] | Neuren Pharmaceuticals Limited [Member] | Research and Development [Member] | North America |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  | $ 10,000 |  | $ 100,000 |  |  |
License Agreements [Member] | Saniona |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 28,000 |  |  |  |  |  |  |  |  |  |
License Agreements [Member] | Saniona | Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  | $ 28,000 |  |  |  |  |  |
License Agreements [Member] | NNZ-2591 [Member] | Development Commercialization and Sales Milestones |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments payable |  | 831,300 |  |  |  |  |  |  |  |  |
Maximum |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments payable |  |  |  |  |  |  | $ 3,500,000 |  |  |  |
Maximum | License Agreements [Member] | Neuren Pharmaceuticals Limited [Member] | North America |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments payable |  | $ 426,300 |  | $ 455,000 |  |  |  |  |  |  |
Maximum | License Agreements [Member] | Saniona |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments payable | 582,000 |  |  |  |  |  |  |  |  |  |
Maximum | License Agreements [Member] | Saniona | Development Commercialization and Sales Milestones |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments payable | 147,000 |  |  |  |  |  |  |  |  |  |
Maximum | License Agreements [Member] | Saniona | Sales |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments payable | $ 435,000 |  |  |  |  |  |  |  |  |  |

X
- Definition Collaboration Agreement, Cost Splits Description + References No definition available. + Details
Name: | acad_CollaborationAgreementCostSplitsDescription
Namespace Prefix: | acad_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangements Upfront consideration and transaction Payment. + References No definition available. + Details
Name: | acad_CollaborativeArrangementsUpfrontConsiderationAndTransactionPayment
Namespace Prefix: | acad_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangements upfront license fee. + References No definition available. + Details
Name: | acad_CollaborativeArrangementsUpfrontLicenseFee
Namespace Prefix: | acad_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangements upfront payment. + References No definition available. + Details
Name: | acad_CollaborativeArrangementsUpfrontPayment
Namespace Prefix: | acad_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition PRV liability + References No definition available. + Details
Name: | acad_PrvLiability
Namespace Prefix: | acad_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill. + References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetImpairment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details
Name: | us-gaap_RestrictedCashNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=acad_CorporateCreditCardProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=acad_FleetProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=acad_StokeTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=acad_LicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=acad_NeurenPharmaceuticalsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=acad_SanionaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=acad_Nnz2591Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=acad_DevelopmentCommercializationAndSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_SalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |